Using aspirin to prevent and treat cancer

Area of Science:

• Oncology
• Pharmacology
• Preventive Medicine

Background:

• Observational studies suggest regular aspirin use correlates with a lower incidence of colorectal cancer (CRC).
• Evidence indicates aspirin use can significantly lower colorectal dysplasia in high-risk individuals.
• Numerous studies show a consistent 20-30% preventive effect of aspirin on overall cancer incidence and mortality.

Approach:

• Review of long-term observational retrospective and prospective studies.
• Analysis of randomized controlled trials (RCTs) on aspirin for CRC prevention.
• Examination of preclinical studies in rodent models (chemically induced and genetically modified).
• Evaluation of clinical studies on aspirin's impact on cancer metastasis and survival.

Key Points:

• RCTs on aspirin for CRC prevention yielded conflicting results, potentially due to patient factors like age and body size.
• Preclinical studies demonstrate aspirin's efficacy in reducing colonic dysplasia and polyp formation.
• Aspirin treatment inhibited cancer cell growth in animal models, suggesting therapeutic potential.
• Clinical data indicates aspirin use before and after cancer diagnosis may reduce metastasis and improve survival.

Conclusions:

• Aspirin exhibits significant anticancer activity, with evidence supporting its role in cancer prevention and treatment.
• The antiplatelet actions of aspirin are crucial to its anticancer effects, particularly in reducing cancer metastasis.
• Ongoing research and conflicting recommendations highlight the need for further investigation into optimal aspirin use for cancer prevention.